Skip to content
Altius – Lifestyle
Author:
Skye Bioscience, Inc.
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
August 14, 2026
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
May 20, 2026
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
April 7, 2026
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
April 2, 2026
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
March 5, 2026